Company: PSTV
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001140361-25-013256
Chunk: 22

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 22
---
 are exercised pursuant to the “zero exercise price” provision set forth in Series B Warrant, which is referred to in the Series B Warrant as an “alternative cashless exercise.” For more information regarding the reset provision, see “—Reset Provision” below. The Series A Warrants are exercisable only following stockholder approval and expire five (5) years thereafter. The number of securities issuable under the Series A Warrant is subject to adjustment as described in more detail in the Series A Warrant. The Series A Warrants are also subject to anti-dilution protection upon any subsequent transaction at a fixed price lower than the warrant exercise price then in effect, as more fully described in the Series A Warrants. The Series B Warrants are exercisable only following stockholder approval and expire two and one-half (2.5) years thereafter. The Series B Warrants are exercisable for cash or pursuant to a zero exercise price provision, pursuant to which the Series B Warrants can be exercised without further payment to the Company and for three times the number of shares of Common Stock issuable upon exercise of the Series B Warrants for cash. The terms of the Warrants require that the Company seek such approval as may be required by the rules and regulations of Nasdaq (the “Warrant Stockholder Approval”). Accordingly, pursuant to this proposal we are seeking stockholder approval of the Warrants and the shares of Common Stock issuable thereunder, including without limitation:

| • | to render inapplicable clause (i) of the definition of the Floor Price contained in Section 1.11 of the Series A Warrants and Section 1.10 of the Series B Warrants; |

| • | to give full effect to the adjustment in the exercise price and number of Series A Warrant Shares following a Dilutive Issuance (as defined therein) pursuant to Section 3.2 of the Series A Warrants; |

| • | to give full effect to the zero exercise price provision pursuant to Section 2.3 of the Series B Warrants; |

| • | to consent to any adjustment of the exercise price and number of (i) Series A Warrant Shares pursuant to Section 3.3 of the Series A Warrants, and (ii) Series B Warrant Shares pursuant to Section 3.2 of the Series B Warrants; |

13

TABLE OF CONTENTS

| • | to consent to any adjustment of the exercise price or number of (i) Series A Warrant Shares